ALT - Altimmune Inc.

-

$undefined

N/A

(N/A)

Altimmune Inc. NASDAQ:ALT Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).

Location: 910 Clopper Rd Ste 201S, Maryland, 20878-1361, US | Website: www.altimmune.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

279.7M

Cash

164.9M

Avg Qtr Burn

-17.87M

Short % of Float

31.01%

Insider Ownership

0.80%

Institutional Own.

60.59%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
metabolic dysfunction-associated steatohepatitis

Phase 2b

Data readout

Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease, metabolic dysfunction-associated steatohepatitis

Big Mover™

Susp. Mover™

Phase 2b

Data readout

Phase 2

Update

Phase 1b

Update

Failed

Discontinued

NasoShield (Vaccine) Details
Anthrax, Bacterial infection

Failed

Discontinued

HepTCell Details
Chronic hepatitis B

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued